Publications by authors named "Wujianhong Liu"
Background And Objective: Olaparib + abiraterone has a combined antitumor effect in metastatic castration-resistant prostate cancer (mCRPC), but the efficacy of this combination in patients with DNA damage repair (DDR)-deficient mCRPC progressing after abiraterone is unknown. Our aim was to compare the efficacy of olaparib + abiraterone versus olaparib monotherapy for patients with DDR-deficient mCRPC progressing after abiraterone.
Methods: The study included 86 consecutive patients with DDR-deficient mCRPC progressing after abiraterone: 34 received olaparib + abiraterone, and 52 received olaparib monotherapy.
Introduction: The classic way of diagnosing prostate cancer (PCa) is by conducting the 12-core systematic biopsy (SB). However, it has a low detection rate for clinically significant PCa (csPCa) and can lead to the detection of clinically insignificant PCa (cisPCa). Although MRI-transrectal ultrasound (MRI-TRUS) fusion targeted biopsy (TB) can effectively improve the detection rate of csPCa, it may still miss some cases.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the survival benefits of postoperative chemotherapy versus surgery alone in elderly patients (≥70 years) with early-stage non-small cell lung cancer (NSCLC).
- Using data from the SEER database, the study compared overall survival (OS) and cancer-specific survival (CSS) between two groups: those receiving chemotherapy and those undergoing only surgery.
- Results indicate that postoperative chemotherapy improved survival rates for stage IB-II patients but decreased survival for stage IA patients, suggesting a nuanced benefit based on cancer stage and characteristics.